Panel Discussion: Uncovering the Latest Technology in Preclinical Modelling Through the Promise of Humanized Complement Models in Drug Development

• Evaluating the utility of humanized complement models for testing complement inhibitors
• Delving into their advantages for human targeted agents
• Addressing key challenges such as incomplete humanization, low human protein expression and functional assay development
• Understanding how humanized complement models can be used to inform complement inhibitor dose prediction

Speakers:

Michael Holers

Professor

UCDHSC

Feng Lin

Researcher

Cleveland Clinic

Michael Storek

Cluster Head

Sanofi